Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00877214 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

Name: Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas — clinical trial record (NCT00877214)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MAINTAIN

StatusUnknown

PhasePhase 3

SponsorJurgen Barth

Started2009-04-01

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 22, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.

The purpose of this study is to determine if an extended maintenance therapy with Rituximab in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has advantages compared to a shorter or no maintenance therapy.

Amendment history 1 change detected by DataLookout

2026-09-06

Trial status changed: Active, Not Recruiting → Unknown

Trial Details

NCT Number	NCT00877214
Lead Sponsor	Jurgen Barth Collaborators: Sponsor GmbH
Conditions	Follicular Lymphomas, Immunocytomas, Marginal Zone Lymphomas, Mantle-Cell Lymphomas, Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
Enrollment	1,272 participants
Start Date	2009-04-01
Primary Completion	2024-12 (estimated)
Study Completion	2024-12 (estimated)
Updated on ClinicalTrials.gov	2024-08-22